Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates.
While pharmaceutical companies are more likely to seek patent protection for their inventions, trade secrets can be useful too, particularly following two recent legislative developments, say Andy Sanderson and Ling Zhuang of Potter Clarkson.
The Canadian Intellectual Property Office has updated its guidelines on procedural and examination practices, with some changes affecting biotechnology and medicinal inventions, explain Jason Markwell and Stephanie Anderson of Belmore Neidrauer.
In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report.
Ahead of the Life Sciences Law Forum 2016, which takes place on June 23 at Etc Venues in the City of London, LSIPR previews some of the main discussion points.
IP and innovation in Mexico has come a long way, and the country’s part in international trade treaties will provide further great opportunities, says Nuria Becerril of Becerril, Coca & Becerril.
There are clear rules on the use of patient data in clinical trials in Costa Rica, as well as sanctions for any breaches, explain María del Pilar López and Esteban Monge of Zürcher Lawyers.
India needs to focus more resources on evaluating applications for biologic drugs, while the biosimilar system needs to be tweaked, says Archana Shanker of Anand and Anand.
Africa Harvest is working towards reducing hunger and poverty in some of the world’s poorest countries. Dr Florence Wambugu, founder of the organisation, tells LSIPR more about its work.
There are several rules to watch out for when seeking patent protection for antibodies in Brazil, as Kene Gallois of Daniel Advogados reports.